59.98
0.00 (0.00%)
| Previous Close | 59.98 |
| Open | 59.98 |
| Avg. Volume (3M) | 1,640,071 |
| Market Cap | 2,341,960,960 |
| Price / Book | 8.51 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2024 |
| Diluted EPS (TTM) | -2.25 |
| Total Debt/Equity (MRQ) | 1.36% |
| Current Ratio (MRQ) | 15.97 |
| Operating Cash Flow (TTM) | -65.93 M |
| Levered Free Cash Flow (TTM) | -36.37 M |
| Return on Assets (TTM) | -30.72% |
| Return on Equity (TTM) | -46.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Longboard Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 1.0 |
| Average | 0.25 |
|
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.20% |
| % Held by Institutions | 121.42% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (Truist Securities, 0.03%) | Hold |
| 60.00 (HC Wainwright & Co., 0.03%) | Hold | |
| 60.00 (B. Riley Securities, 0.03%) | Hold | |
| Median | 60.00 (0.03%) | |
| Average | 60.00 (0.03%) | |
| Total | 3 Hold | |
| Avg. Price @ Call | 59.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 Oct 2024 | 60.00 (0.03%) | Hold | 59.08 |
| Truist Securities | 15 Oct 2024 | 60.00 (0.03%) | Hold | 59.08 |
| B. Riley Securities | 14 Oct 2024 | 60.00 (0.03%) | Hold | 58.99 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |